注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司,专注于开发一系列癌症疗法。该公司的主要候选产品包括SNDX-5613和SNDX-6352(axatilimab)。该公司专注于开发SNDX-5613,靶向menin与混合谱系白血病1(MLL1)的结合作用、用于治疗混合谱系白血病基因重排(MLLr)、急性白血病和核磷蛋白1(NPM1)、突变急性髓细胞白血病(AML),以及阻断集束刺激因子1(CSF-1)受体的单克隆抗体axatilimab。该公司的候选产品还包括每周一次的口服小分子恩替诺他,和I类组蛋白去乙酰化酶(HDAC)抑制剂,该抑制剂正在与依西美坦联合进行III期E2112注册临床试验,用于激素受体阳性、人表皮生长因子受体2阴性和乳腺癌评估。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Dennis G. Podlesak | 63 | 2008 | Independent Chairman |
Michael A. Metzger | 51 | 2015 | CEO & Director |
Jedd D. Wolchok | - | 2016 | Member of Scientific Advisory Board |
Hope S. Rugo | - | 2016 | Member of Scientific Advisory Board |
Lisa M. Coussens | - | 2017 | Member of Scientific Advisory Board |
Samir N. Khleif | 58 | 2016 | Member of Scientific Advisory Board |
Jennifer Jarrett | 51 | 2018 | Independent Director |
William Meury | 54 | 2018 | Independent Director |
Martin H. Huber | 61 | 2021 | Independent Director |
Julie R. Brahmer | - | 2015 | Member of Scientific Advisory Board |
George W. Sledge | 71 | 2014 | Member of Scientific Advisory Board |
Keith A. Katkin | 52 | 2017 | Independent Director |
Pierre Legault | 62 | 2017 | Independent Director |
Briggs W. Morrison | 63 | 2015 | Director |
Joseph Paul Eder | - | 2016 | Member of Scientific Advisory Board & Chief Medical Officer |
Ronald M. Evans | 75 | 2016 | Co-Founder, Advisor and Chair of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核